GALDERMA
EST. 1981

MORE TO LOVE WITH Restylane® KYSSE™

Restylane® KYSSE™ is the HA injectable of choice for natural-looking, long-lasting and kissable lips.[1-4*]

ACHIEVE SOFT, NATURAL-LOOKING RESULTS

- Designed with a soft, flexible gel texture[5,6]
- Provides an optimal balance of flexibility and support, enhancing natural lip aesthetics without compromising expression.[7,8]
- Distributes evenly for consistent, natural-looking volume and shape[7-9,§]

RESTYLANE® KYSSE™ DEVELOPED SPECIFICALLY FOR THE LIPS

Developed with passion and movement in mind, Restylane® KYSSE™ is based on Optimal Balance Technology (OBT™[3,6]) to achieve natural-looking and feeling lips that are even more kissable than before treatment.[1,2]

MORE NATURAL-LOOKING, MORE SATISFYING AND MORE KISSABLE AFTER TREATMENT WITH

KYSSE™[†,^,1,2]

XOX

BRING OUT NATURAL BEAUTY

Treated with 0.8mL

Treated with 0.25mL in the upper lip and 0.25mL in the lower lip

Treated with 0.5mL in the upper lip

Treated with 1mL

Treated with Restylane® KYSSE™ in the lips. Actual patients. Individual results may vary.

MORE TO LOVE WITH Restylane® KYSSE™

L I P S

LONG-LASTING results with less:[2,10]

Up to 12 months of **soft, plump, natural-looking lips** with **~20% less** product than competitor product[1,2,10†]

IDEAL balance of flexibility and support:[1,2,5-8,11]

Thanks to **OBT™ technology,** the **soft and flexible** gel texture[5,6] provides balanced volume for smooth, natural-looking and more kissable lips after treatment.[1,2,7–9§]

PATIENT *and* PARTNER satisfaction:[1]

96% of patients would repeat treatment, and **100%** would recommend it to a friend[2]

>96% of patients agreed their lips looked natural[1]

73% agreed their partner's lips had an even more kissable and natural feel than before treatment[1]

SAFETY/TOLERABILITY profile well established across diverse patients:[2,7,10,12-13]

Proven clinical efficacy and safety/tolerability results in different skin types, colours, and tones[2,7,10]

Significantly less swelling than competitor product**[12] with **low occurrence** of implant site nodules, hypersensitivity reactions, and papules[2,12,13]

Restylane® KYSSE™ No. 1 INJECTORS CHOICE* FOR THE LIPS

100% of patients were **happy with their lip style** and reported **aesthetic improvement after treatment with Restylane® KYSSE™¶*[1]

Find out more

KISS & SMILE™ HIT™ by GALDERMA

Elevate Restylane® KYSSE™ results by integrating other products in the Galderma Aesthetics range to offer your patients Holistic Individualised Treatments (HIT™)

iGAIN.galderma.com.au

Follow us @GAINbyGalderma.au

HA, hyaluronic acid; **HIT™**, Holistic Individualised Treatment; **OBT™**, Optimal Balance Technology.

* Restylane® KYSSE™ was chosen to be the injectable HA filler of choice for the lips based on a survey of 471 HCPs in US, Brazil, Thailand and Germany.

† Based on publication analyses that demonstrate no other HA filler competitor has conducted or published such studies; therefore, supported – by proxy – by the absence of evidence.

^ Up to 8 weeks after treatment, 73% of patient's partners agreed that their patients' lips had a more kissable and natural feel. N=49.

**Patients treated with Juvéderm® Ultra Smile® (also labelled as Juvéderm® Ultra Plus® and Juvéderm® Ultra 3®) had significantly more swelling than patients treated with Restylane® KYSSE™ ($p<0.001$).[12] Juvéderm® is a registered trademark of Allergan Holdings France SAS.

‡ A significantly smaller volume of Restylane KYSSE™ was required to achieve comparable lip fullness vs. Juvéderm Volbella XC (1.82 mL vs. 2.24 mL; $p<0.001$).[10]

§ Compared with baseline.[1]

¶ As assessed by the Galderma KISSABILITY Questionnaire, which was provided at Week 4 and returned at Week 8.

References: 1. Bertucci V et al. J Cosmet Dermatol. 2021;20(5):1499-504. **2.** Hilton S et al. Dermatol Surg. 2018;44(2):261-9. **3.** InCrowd Lip filler survey 2024. **4.** IFU Restylane® KYSSE™. **5.** Rogerio V et al. J Stomatol Oral Maxillofac Surg. 2022;123(4): 440-7. **6.** Galderma. Data on file. MA-43049. xStrain and G' (Global). **7.** Bertucci V et al. J Drugs Dermatol. 2021;20(4):402-8. **8.** Nikolis A et al. Dermatol Surg. 2021;47(5):e168-73. **9.** Lundgren B et al. J Drugs Dermatol. 2018;17:982-6. **10.** Weiss R et al. Dermatol Surg. 2021;47(4):527–32. **11.** Öhrlund A et al. J Drugs Dermatol. 2024; 23(1):1332–6. **12.** Hilton S et al. J Cosmet Dermatol. 2023;22(1):119–27. **13.** Cohen JL et al. Dermatol Surg. 2022;48(1):152–3.

Restylane®, Class III medical device, is a gel containing hyaluronic acid 20 mg/mL and lidocaine 0.3% for injection into or below the skin to smooth facial wrinkles and enhance lips by restoring volume and fullness. Do not inject into blood vessels as this may lead to a lack of blood supply to the skin and ulceration and scarring. Do not use in patients with severe allergies manifested by a history of anaphylaxis or multiple severe allergies, or known hypersensitivity to lidocaine, amide-type local anaesthetics or streptococcal proteins. Restylane® should not be used in or near sites where there are active skin disease, inflammation or infection, or where a permanent implant has been placed. Do not use in patients with bleeding disorders or in those who are taking thrombolytics or anticoagulants and caution when using in patients taking other medicines which prolong bleeding times. Use with caution in patients on immunosuppressive therapy or when treating facial areas with limited soft tissue support or cover such as the periorbital area. Treatment benefits are instant, do not affect facial expression and results usually last 6-12 months. Ongoing treatments are needed to maintain best results. After a Restylane® treatment patients may experience some degree of redness, swelling, pain or tenderness, itching and/or bruising which may only last a few days. Post inflammatory pigmentation changes may occur after dermal filler injections in people with dark skin. Inflammatory reactions may occur up to two to four weeks after treatment in rare cases. Other rare adverse effects may include allergy, infection, granuloma formation, persistent discoloration at the injection site, and ulceration of the skin. Exposure to excessive sunlight or extreme cold should be avoided until redness or swelling has resolved. Use with caution before or after laser treatment or chemical peel. Restylane® has not been tested in pregnant or breast feeding women. Unfunded in NZ. Product and treatment costs apply.

Galderma Australia Pty Ltd, Level 18, 1 Denison St, North Sydney, NSW 2060, Australia. ABN 12 003 976 930. Distributed in NZ by Healthcare Logistics, 58 Richard Pearse Drive, Airport Oaks, Mangere 2022. Phone: 1800 144 944 (AUS), 0800 174 104 (NZ). Restylane® and Galderma are registered trademarks of Galderma Holding S.A. NZ-RES-2500001. TAPS Approval No: NP22197. February 2025.

FOR HCP USE ONLY

GALDERMA
EST. 1981